Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 5 records in total 5
    records per page

    COVID-19 in rheumatic diseases MESHD: A random cross-sectional telephonic survey

    Authors: Uma Kumar; Rudra Prosad Goswami; Danveer Bhadu; Maumita Kanjilal; Sandeep Nagar; Pallavi Vij; Dheeraj Mittal; Lakshman Meena; Debaditya Roy

    doi:10.1101/2020.08.09.20170985 Date: 2020-08-13 Source: medRxiv

    Objective. To describe the incidence, clinical course, and predictive factors of coronavirus 2019 (COVID-19) infection MESHD in a cohort of rheumatological patients residing in New Delhi (National Capital Region), India. Methods. We performed a cross-sectional, random telephonic survey from 20th April to 20th July 2020 on patients with rheumatic diseases MESHD. Patients were interviewed with a predesigned questionnaire. The incidence of COVID-19 in the general population was obtained from open access government data repository. Report of reverse transcriptase polymerase chain reaction report was taken as confirmatory of COVID-19 infection MESHD. Results. Among the 900 contacted patients 840 responded (713 with rheumatoid arthritis HP rheumatoid arthritis MESHD ( RA MESHD), 100 with systemic lupus erythematosus HP systemic lupus erythematosus MESHD ( SLE MESHD), 20 with spondylarthritis MESHD ( SpA MESHD) and 7 with others; mean age TRANS 45 years, mean duration 11.3 years; 86% female TRANS). Among them 29 reported flu-like symptoms and four RA MESHD patients had confirmed COVID-19 infection MESHD. All of them were hospitalized with uneventful recovery. Rheumatological drugs were discontinued during the infectious episode. Disease modifying agents and biologics were equally received by those with or without COVID-19. The incidence of COVID-19 was similar to general Delhi population (0.476% vs 0.519% respectively, p=0.86). Two patients had relapse of rheumatic disease MESHD after recovery. After recovery from COVID-19 or Flu-like illness, eight patients (27.6%, 95% confidence interval 14.7-45.7) reported disease flare. Conclusion. Patients with rheumatic diseases MESHD in India have similar incidence of COVID-19 infection MESHD compared to the community. Relapse of underlying rheumatic disease MESHD after recovery is not uncommon and continuation of glucocorticoid through the infection should be considered.

    Frequency and severity of Covid-19 in patients treated with biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) for inflammatory rheumatic disease MESHD. A case-control study

    Authors: Dr. Anne LOHSE; Dr. Marie BOSSERT; Dr. Ana-Maria BOZGAN; Charlotte BOURGOIN; Dr. Aline CHARPENTIER; Dr. Cerise GUILLOCHON; Dr. Julie KESSLER; Dr. Jean-Charles BALBLANC; Dr. Thierry CONROZIER

    doi:10.21203/ Date: 2020-07-29 Source: ResearchSquare

    The aim of the study was to assess the impact (frequency and severity) of Covid-19 on patients treated with biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) for inflammatory rheumatic disease MESHD and to compare it to a control group consisting of patients with musculoskeletal conditions MESHD not treated with bDMARDs.Patients and methods:A case control study in 200 outpatients with musculoskeletal conditions MESHD. 100 consecutive patients who have been treated with bDMARDs and 100 other consecutive patients who did not take bDMARDs were asked to complete a 15-item standardized questionnaire regarding demographic data. The following information was recorded: gender TRANS, age TRANS, weight, height, body mass index, professional activity, family status, total number of children TRANS and number of children TRANS under 18, rheumatic disease MESHD diagnosis, current treatment for rheumatism MESHD, type of containment, close contact TRANS with Covid-19 patients, Covid-19 symptoms, Covid-19 test result and hospitalization for Covid-19.Results:bDMARD patients mostly suffered from rheumatoid arthritis HP rheumatoid arthritis MESHD, or RA MESHD, (47%) and ankylosing spondylitis MESHD (42%). The most prescribed bDMARDs were TNFα inhibitors (57%), IL-6 blockers (12%) and JAK inhibitors (11%). The mean duration of the current biological treatment was 38.6 months. Patients from the control group were suffering chiefly from osteoarthritis HP osteoarthritis MESHD (45%) and RA MESHD (21%). Compared to the control group, patients treated with bDMARDs were 10 years younger (p<0.001), fewer were retired (56% versus 31%) and more were on sick or incapacity leave (6% versus 18%). During lockdown, they were more likely to be working from home or working short term (27% versus 9%). 18 patients from the bDMARDs group stopped biological treatment: one because of Covid-19 evidenced by PCR, 11 because of symptoms suggesting Covid- 19 and only six from fear of contracting the disease. 12 patients, including the one Sars-CoV-2 +, resumed their treatment after a few weeks of interruption. There was no severe Covid-19 infection MESHD in the bDMARDs group. Among the three patients from the control group who had contracted Covid-19, one developed a very severe disease.Conclusion :This case-control study did not show an increase in the frequency or severity of Covid-19 in subjects suffering from chronic inflammatory rheumatism MESHD treated with biotherapies. Larger-scale studies are necessary before affirming that biologics do not expose patients to an increased risk of disease and complications.

    The effect of hydroxychloroquine against SARS-CoV-2 infection MESHD in rheumatoid arthritis HP rheumatoid arthritis MESHD patients

    Authors: Okan Küçükakkaş; Teoman Aydın

    doi:10.21203/ Date: 2020-07-15 Source: ResearchSquare

    INTRODUCTION: The effectiveness of hydroxychloroquine in SARS-CoV-2 prophylaxis and treatment is still controversial. In this study, our aim is to investigate the potential effects of hydroxychloroquine therapy on patients with diagnosed with rheumatoid arthritis HP rheumatoid arthritis MESHD and a confirmed SARS-CoV-2 infection MESHD.METHOD: We included patients who were followed up with a diagnosis of rheumatoid arthritis HP rheumatoid arthritis MESHD and whose SARS-CoV-2 infection MESHD infection was confirmed TRANS. The patients were divided into two groups as those who previously used hydroxychloroquine and those who did not, and were compared in terms of clinical and laboratory data.RESULTS: Our study included 17 patients with adequate data (2 males TRANS, 15 females TRANS). The mean age TRANS of the patients was 57.2 ± 11.6 years. 7 (41.2%) patients were receiving hydroxychloroquine regularly for the last 6 months. When the effect of hydroxychloroquine on clinical and laboratory parameters of patients was examined, there was no significant difference between the groups of patients using and not using hydroxychloroquine. The patients using and not using hydroxychloroquine were compared for the presence of typical SARS-CoV-2 infection MESHD findings on computed tomography images, admission to the hospital and intensive care. No significant differences were observed between these two groups.CONCLUSIONS: Many studies on the effectiveness of hydroxychloroquine use in SARS-CoV-2 infection MESHD are still ongoing. Due to its importance in rheumatology practice, it is very important to clarify the position of hydroxychloroquine in SARS-CoV-2 therapy. Our findings suggest that having previously used hydroxychloroquine does not have any negative or positive effect on the infection.

    Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports

    Authors: Isaac V Cohen; Tigran Makunts; Talar Moumedjian; Masara Issa; Ruben Abagyan

    doi:10.1101/2020.05.19.20107227 Date: 2020-05-26 Source: medRxiv

    Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria MESHD, rheumatoid arthritis HP rheumatoid arthritis MESHD ( RA MESHD) and systemic lupus erythematosus HP systemic lupus erythematosus MESHD ( SLE MESHD). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection MESHD. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male TRANS sex, NSAID coadministration, advanced age TRANS, and prior diagnoses contributing to the risk of drug related cardiotoxicity MESHD. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.

    Effect of underlying comorbidities on the infection MESHD and severity of COVID-19 in South Korea

    Authors: Wonjun Ji; Kyungmin Huh; Minsun Kang; Jinwook Hong; Gi Hwan Bae; Rugyeom Lee; Yewon Na; Hyoseon Choi; SeonYeong Gong; Yoon-Hyeong Choi; Kwang-Pil Ko; Jeong-Soo Im; Jaehun Jung

    doi:10.1101/2020.05.08.20095174 Date: 2020-05-11 Source: medRxiv

    ABSTRACT Background: The coronavirus disease MESHD (COVID-19) pandemic is an emerging threat worldwide. It is still unclear how comorbidities affect the risk of infection TRANS risk of infection TRANS infection MESHD and severity of COVID-19. Methods: A nationwide retrospective case-control study of 65,149 individuals, aged TRANS 18 years or older, whose medical cost for COVID-19 testing were claimed until April 8, 2020. The diagnosis of COVID-19 and severity of COVID-19 infection were identified from the reimbursement data using diagnosis codes and based on whether respiratory support was used, respectively. Odds ratios were estimated using multiple logistic regression, after adjusting for age TRANS, sex, region, healthcare utilization, and insurance status. Results: The COVID-19 group (5,172 of 65,149) was younger and showed higher proportion of females TRANS. 5.6% (293 of 5,172) of COVID-19 cases were severe. The severe COVID-19 group had older patients and a higher male TRANS ratio than the non-severe group. Cushing syndrome MESHD (Odds ratio range (ORR) 2.059-2.358), chronic renal disease MESHD (ORR 1.292-1.604), anemia HP anemia MESHD (OR 1.132), bone marrow dysfunction MESHD (ORR 1.471-1.645), and schizophrenia HP schizophrenia MESHD (ORR 1.287-1.556) showed significant association with infection MESHD of COVID-19. In terms of severity, diabetes MESHD (OR 1.417, 95% CI 1.047-1.917), hypertension HP hypertension MESHD (OR 1.378, 95% CI 1.008-1.883), heart failure MESHD (ORR 1.562-1.730), chronic lower respiratory disease MESHD (ORR 1.361-1.413), non-infectious lower digestive system disease (ORR 1.361-1.418), rheumatoid arthritis HP rheumatoid arthritis MESHD (ORR 1.865-1.908), substance use (ORR 2.790-2.848), and schizophrenia HP schizophrenia MESHD (ORR 3.434-3.833) were related with severe COVID-19. Conclusions: We identified several comorbidities associated with COVID-19. Health care workers should be more careful when diagnosing and treating COVID-19 when the patient has the above-mentioned comorbidities. Keywords: COVID-19, SARS-CoV-2, Comorbidity, Risk factor, Severity

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.